Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.46−0.06 (-1.70%)
Close on Nov 17, 2026Market cap $224.08MP/E –Yield –
Immuneering operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Immuneering's operating income for the twelve months ending Sep 30, 2026 was -$73.88M. For fiscal 2025 it was -$59.38M. The highest annual figure on record is -$17.08M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$59.38M | – |
| FY2024 | Dec 31, 2024 | -$64.07M | – |
| FY2023 | Dec 31, 2023 | -$58.41M | – |
| FY2022 | Dec 31, 2022 | -$51.74M | – |
| FY2021 | Dec 31, 2021 | -$33.89M | – |
| FY2020 | Dec 31, 2020 | -$17.08M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.79M | – |
| Q2 FY2026 | Jun 30, 2026 | -$19.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.75M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.33M | – |
| Q4 FY2023 | Dec 31, 2023 | -$16.30M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.12M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.54M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.24M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.61M | – |
See a number that looks wrong?